Early psoriatic arthritis: facing the challenge

Area of Science:

• Rheumatology
• Immunology

Background:

• Psoriatic arthritis (PsA) leads to joint damage, reduced quality of life, and increased mortality.
• Historically, treatments did not halt PsA progression until the advent of anti-tumor necrosis factor (anti-TNF) agents.
• Anti-TNF therapy enables arresting joint damage progression in PsA patients.

Purpose of the Study:

• To extend the "window of opportunity" concept for early PsA assessment and management.
• To address the challenges in integrating early PsA assessment into standard clinical practice.
• To propose a paradigm for identifying early PsA patients in routine care.

Main Methods:

• Review of current clinical rheumatology objectives and treatment advancements.
• Analysis of the "window of opportunity" concept's application to PsA.
• Identification of barriers to implementing early PsA services.

Main Results:

• The "window of opportunity" concept, successful in rheumatoid arthritis, is applicable to PsA.
• Anti-TNF agents allow for the arrest of joint damage progression.
• Early PsA assessment is currently limited to research settings due to practical challenges.

Conclusions:

• Early intervention in PsA, similar to rheumatoid arthritis, can yield successful outcomes.
• Implementing early PsA assessment services faces significant hurdles in standard clinical practice.
• A new paradigm is needed to facilitate early PsA patient identification and management.